Table 2 Subgroup analysis to explore heterogeneity in the estimate of the pooled prevalence of pulmonary function abnormalities
Studies (k) | Patients (n) | Pooled prevalence (95% CI) | I2 (%) | P value | |
|---|---|---|---|---|---|
Impaired diffusion capacity | 19 | 2573 | 0.35 (0.30–0.41) | 87.72 | |
Follow-up interval after initial presentation (months) | 0.115 | ||||
6 | 10 | 1450 | 0.39 (0.34–0.45) | 74.42 | |
12 | 9 | 1123 | 0.31 (0.21–0.40) | 91.70 | |
Risk of bias of study | 0.931 | ||||
Low-to-moderate | 12 | 1803 | 0.35 (0.28–0.43) | 91.31 | |
Moderate-to-high | 7 | 770 | 0.36 (0.29–0.42) | 69.20 | |
Proportion of patients with severe COVID-19 (%)a | 0.015 | ||||
≥ 50 | 13 | 2105 | 0.39 (0.35–0.44) | 73.90 | |
< 50 | 5 | 398 | 0.24 (0.12–0.35) | 88.62 | |
Reduced forced vital capacity | 15 | 2679 | 0.08 (0.06–0.11) | 85.51 | |
Follow-up interval after initial presentation (months) | 0.006 | ||||
6 | 7 | 1201 | 0.13 (0.08–0.19) | 89.57 | |
12 | 8 | 1478 | 0.05 (0.03–0.07) | 69.29 | |
Risk of bias of study | 0.033 | ||||
Low-to-moderate | 10 | 2219 | 0.06 (0.04–0.08) | 78.97 | |
Moderate-to-high | 5 | 550 | 0.15 (0.07–0.24) | 87.16 | |
Proportion of patients with severe COVID-19 (%)a | 0.544 | ||||
≥ 50 | 10 | 2218 | 0.08 (0.05–0.10) | 86.82 | |
< 50 | 3 | 288 | 0.06 (0.00–0.11) | 75.23 | |